Year in Review | Published:

Breast cancer in 2010

Novel targets and therapies for a personalized approach

Nature Reviews Clinical Oncology volume 8, pages 6566 (2011) | Download Citation

2010 has been another prolific year in breast cancer research with a number of original observations bringing us closer to personalized care. Studies with novel targeted agents in defined breast cancer subgroups have revealed exciting developments and highlight the importance of patient selection.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244 (2010).

  2. 2.

    et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251 (2010).

  3. 3.

    et al. Final efficacy and safety results of a randomized phase II study of the PARP inhibitor iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC) [abstract LBA11]. Ann. Oncol. 21 (Suppl. 8), viii5 (2010).

  4. 4.

    et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 2698–2704 (2010).

  5. 5.

    et al. Phase II study of the antibody-drug conjugate trastuzumab-DM1 (T-DM1) for the treatment of HER2-positive breast cancer following prior HER2-directed therapy. J. Clin. Oncol. (in press).

  6. 6.

    et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450G) [abstract LBA3]. Ann. Oncol. 21 (Suppl. 8), viii2 (2010).

  7. 7.

    et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138–1144 (2010).

  8. 8.

    et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).

  9. 9.

    et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239–3247 (2010).

  10. 10.

    et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55–65 (2010).

Download references

Author information

Affiliations

  1. Massachusetts General Hospital Cancer Center, 55 Fruit Street, Laurence House, Boston, MA 02114, USA

    • Michaela J. Higgins
    •  & José Baselga

Authors

  1. Search for Michaela J. Higgins in:

  2. Search for José Baselga in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to José Baselga.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrclinonc.2010.217

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing